2 completed, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Integro Theranostics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer LS301-IT 0.1 mg/kg - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Active not recruiting | Integro Theranostics | 35 | 2025-12-08 | 2026-11-03 |
| A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer LS301-IT - Lung Cancers | Phase 1 | Completed | Integro Theranostics | 24 | 2024-11-07 | 2026-05-19 |
| LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg - Breast Cancer, DCIS | Phase 1 / Phase 2 | Completed | Integro Theranostics | 22 | 2023-07-14 | 2026-05-20 |
Lung Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1)
United States (3)
Robert Honigberg, MD (2) · Dan Thompson (1)